Target intelligence / Profile preview

Zinc transporter ZIP6 (LIV-1)

Target
LIV-1
Molecular classification
Transporter
01

Overview

Zinc transporter ZIP6 (also known as LIV-1 or SLC39A6) is a multi-pass transmembrane protein belonging to the solute carrier family 39 (SLC39) of zinc transporters. It plays a critical role in maintaining intracellular zinc homeostasis by mediating zinc influx from the extracellular space into the cytoplasm. ZIP6 is highly expressed in hormonally controlled tissues such as the breast and prostate, and its expression is upregulated by estrogen. In cancer, ZIP6 is frequently overexpressed, particularly in breast, prostate, and pancreatic cancers, where it promotes epithelial-mesenchymal transition (EMT), cell migration, and metastasis, often by forming a heterodimer with ZIP10. Because of its high expression on the surface of tumor cells and limited expression in normal tissues, ZIP6 has emerged as an attractive target for antibody-drug conjugates (ADCs). Prominent therapeutic candidates targeting ZIP6 include ladiratuzumab vedotin (SGN-LIV1A), which delivers a cytotoxic microtubule inhibitor payload to induce mitotic arrest and apoptosis in cancer cells.

Other names
Solute carrier family 39 member 6LIV-1ZIP6SLC39A6Estrogen-regulated protein LIV-1Zrt- and Irt-like protein 6ZIP-6LIV1
02

Mechanism of action

Antibody-drug conjugate (ADC) targeting cell-surface ZIP6 to deliver cytotoxic payloads (such as microtubule inhibitors or topoisomerase I inhibitors), leading to receptor-mediated endocytosis, intracellular drug release, mitotic arrest, and apoptosis.

03

Biological functions

Zinc transportCell proliferationEpithelial-mesenchymal transitionCell migrationMitosisImmune response
04

Disease associations

Cancer
05

Safety considerations

NeutropeniaPeripheral neuropathyAlopeciaAnemiaFatigueNauseaOn-target, off-tumor toxicity in normal tissues expressing ZIP6Potential lack of efficacy in certain breast cancer subtypes
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

LIV-1 expression levelSLC39A6 expression levelEstrogen receptor (ER) statusTriple-negative breast cancer (TNBC) status

Beyond the preview

Go deeper on Zinc transporter ZIP6 (LIV-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zinc transporter ZIP6 (LIV-1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call